MEERKAT trial – Talk Bio

Actionable Insights Powered by AI

Mixed Results for Roche’s Vamikibart in Phase III Uveitic Macular Edema Trials

5 days ago talkbio0Tagged central subfield, Clinical Relevance, MEERKAT trial, ocular adverse events, Phase 3 Clinical Trials, Roche (company), SANDCAT trial, Thick, uveitic macular edema, Vamikibart, vision improvement

Roche; vamikibart; uveitic macular edema; Phase III trials; MEERKAT trial; SANDCAT trial; vision improvement; central subfield thickness; clinical significance; ocular adverse events